ImmunoGen, Inc. (IMGN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Waltham, MA, United States. The current CEO is Mark Joseph Enyedy.
IMGN has IPO date of 1989-11-17, 277 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $8.73B.
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing antibody-drug conjugate (ADC) therapies for cancer treatment. The company's lead candidate, mirvetuximab soravtansine, targets folate-receptor alpha and is in Phase III trials for platinum-resistant ovarian cancer, while Pivekimab sunirine, a CD123-targeting ADC, is in Phase II development for acute myeloid leukemia and related blood cancers. ImmunoGen maintains a robust pipeline of preclinical programs and strategic collaborations with major pharmaceutical companies including Roche, Amgen, Bayer, Eli Lilly, Novartis, and others. Founded in 1980 and headquartered in Waltham, Massachusetts, the company leverages proprietary ADC technology to advance novel cancer therapies.
